The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 270-276

  Valentini, Gabriele ^a   Iudici, Michele ^a   Walker, Ulrich A ^b   Jaeger, Veronika K ^b   Baron, Murray ^c   Carreira, Patricia ^d   Czirják, László ^e   Denton, Christopher P ^f   Distler, Oliver ^g   Hachulla, Eric ^h   Herrick, Ariane L ⁱ   Kowal Bielecka, Otylia ^j   Pope, Janet ^k   Möller Ladner, Ulf ^l   Riemekasten, Gabriela ^m   Avouac, Jerome ⁿ   Frerix, Marc ^l   Jordan, Suzana ^g   Minier, Tönde ^e   Siegert, Elise ⁿ   Ong, Voon H ^f   Vettori, Serena ^a   Allanore, Yannick ^o   more..

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSITY OF PÉCS   (Hungary)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIV LILLE   (France)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l JUSTUS LIEBIG UNIVERSITY   (Germany)

^m University of Löbeck   (Germany)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o Institut Cochin   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSESSMENT; EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX; FEMALE; FINGER ULCER; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MEDSGER SEVERITY SCORE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS; COMPLICATION; EUROPE; FOLLOW UP; MIDDLE AGED; REPRODUCIBILITY; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; ROC CURVE; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84987797058     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209768     Document Type: Article

References (40)

1. Valentini G. The assessment of the patient with Systemic Sclerosis. Autoimmun Rev 2003;2:370-6.
2. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
3. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
4. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008;47:1185-92.
5. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007;66:754-63.
6. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-Term survival in systemic sclerosis. 2014;66:1625-35.
7. Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med 2010;4: 133-47.
8. Valentini G, Della Rossa A, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
9. Valentini G, D'Angelo S, Della Rossa A, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
10. Shao J, Tu D. The jackknife and the bootstroop. New York: Springer, 1995.
11. Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
12. http://scholar.google.it/citationsview-op=view-citation&hl=it&user=3z2zFpUAAAAJ&citation-for-view=3z2zFpUAAAAJ:9yKSN-GCB0IC (accessed Sep 2015).
13. Fan X, Pope J, The Canadian Scleroderma Research Group, Baron M. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010;30:1205-10.
14. Hanke K, Dahnrich C, Bruchner CS, et al. Diagnostic value of anti-Topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009;11:R28.
15. Qi Q, Guo Q, Tan G, et al. Predictors of the scleroderma phenotype in fibroblasts from systemic sclerosis patients. J Eur Acad Dermatol Venereol 2009;23:160-8.
16. Hudson M, Steele R., Canadian Scleroderma Research Group (CSRG), Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93-8.
17. Foocharoen C, Distler O, Becker M, et al. Clinical correlations of hypocomplementaemia in systemic sclerosis: An analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol 2012;41:243-6.
18. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
19. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8.
20. D'Andrea A, Naeije R, Grunig E, et al. Echocardiography of the pulmonary circulation and right ventricular function: exploring the physiologic spectrum in 1480 normal subjects. Chest 2014;145:1071-8.
21. Standardization of Spirometry 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
22. American Thoracic Society. Single breath Carbon monoxide diffusing capacity (transfer Factor). Recommendation of a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-98.
23. van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: An American College of Rheumatology-European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.
24. Cutolo M, Sulli A, Pizzorni C, et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.
25. Medsger TA Jr, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(Suppl 29):S42-6.
26. Harel D, Hudson M, Iliescu A, et al. Summed and weighted summary scores for the Medsger Disease Severity Scale compared with the physician's global assessment of disease severity in systemic sclerosis. J Rheumatol 2016;43:1510-18.
27. Meyer OC, Fertig N, Lucas M, et al. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.
28. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
29. Steen VD, Medsger TA Jr. The palpable tendon friction rub: An Important physical examination finding in patients with Systemic Sclerosis. Arthritis Rheum 1997;40:1146-51.
30. Hudson M, Walker JG, Fritzler M, et al. Hypocomplementemia in systemic sclerosis-clinical and serological correlations. J Rheumatol 2007;34:2218-23.
31. Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60:585-91.
32. Avouac J, Walker UA, Hachulla E, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study. Ann Rheum Dis 2016;75:103-9.
33. Muangchan C, Harding S, Khimdas S, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012;64:1405-14.
34. Walker JG, Steele RJ, Schnitzler M, et al. The association between disease activity and duration in systemic sclerosis. J Rheumatol 2010;37:2299-306.
35. Mihai C, Landewé R, van der Heijde D. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 2016;75:681-6.
36. Tashkin DP, Volkmann ER, Tseng CH, et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 2016;75:374-81.
37. Wiese AB, Berrocal VJ, Furst DE, et al. Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. Arthritis Care Res (Hoboken) 2014;66:1731-9.
38. Diaconu D, Vonk M, Denton C, et al. Disease activity criteria for patients with early systemic sclerosis [abstract]. Ann Rheum Dis 2009;68(Suppl 3):P275.
39. Minier T, Nagy Z, Bálint Z, et al. Construct validity of the European Scleroderma Study Group activity index and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology (Oxford) 2010;49:1133-45.
40. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.